Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
50 participants
INTERVENTIONAL
2013-07-31
2014-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis
NCT06076304
Nebulized Nasal Steroids
NCT07270302
Anti-Inflammatory Agent in Sinusitis
NCT02874144
Comparing Budesonide Via MAD or INSI Prospective Cohort Study
NCT04267042
NasoNeb Delivery of an Intranasal Steroid
NCT01270256
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral
Oral drug (methylprednisolone) administration
methylprednisolone
Oral 32mg/8d-16mg/4d-8mg/4d
Metered dose inhaler
Budesonide
Budesonide by metered dose inhaler
Nebulized
Budesonide
Budesonide by nebulization
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
methylprednisolone
Oral 32mg/8d-16mg/4d-8mg/4d
Budesonide
Budesonide by metered dose inhaler
Budesonide
Budesonide by nebulization
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Age under 18y
* Use of antibiotics
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
G.Reychler
Docteur Gregory Reychler
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregory Reychler, PhD
Role: STUDY_DIRECTOR
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Philippe Rombaux, Prof PhD
Role: STUDY_DIRECTOR
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Coralie Colbrant, PT
Role: PRINCIPAL_INVESTIGATOR
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sinusitis001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.